ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC "
Episode Synopsis
Faculty: Luis Paz-Ares, MD, PhD
Faculty: Lauren A. Byers, MD
This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.
In God we trust